

Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m²) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft

NCT04989491

Status	RECRUITING
Phase	Phase 4
Sponsor	University Hospital, Strasbourg, France
Enrollment	120 participants

Plain Language Summary

This study tests whether a single dose of rituximab (a medication that affects the immune system) can prevent a dangerous virus called Epstein-Barr virus (EBV) from infecting kidney transplant recipients who have never had EBV before but received a kidney from a donor who has.

****You may be eligible if...****

- You are 18 or older and received a kidney (or kidney-pancreas) transplant
- You have never been infected with EBV (confirmed by blood tests)
- Your donor had EBV
- You are willing to use contraception during the study
- You are enrolled in a social security or health insurance scheme

****You may NOT be eligible if...****

- You have an active hepatitis B infection
- You are allergic to rituximab
- You have severe immune system problems
- You have severe heart failure
- You are pregnant or breastfeeding
- You are currently in another drug clinical trial
- You have a psychiatric condition that would prevent study participation

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (7)

- Adult patients (age ≥18 years at transplantation)
- Kidney and kidney pancreas simultaneous transplantation
- EBV seronegative patients (IgG anti EBNA, IgG anti VCA and IgM anti VCA negative) (from 6 months before transplantation to the day of transplantation, included)
- Patient who have given written informed consent
- Negative pregnancy test and use of contraception during all the study

... and 2 more (see full listing online)

Exclusion (11)

<https://clinicaltrials.gov/study/NCT04989491>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

- Patient with known HBV active infection
 - Allergy to Rituximab
 - Severe Immune deficiency
 - Severe cardiac insufficiency
 - Pregnant or lactating women
- ... and 6 more (see full listing online)

Locations (1 total)

Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France